The medtech segment achieved operational revenue growth of 4.4% despite ongoing weaknesses in the Chinese market. Notably, ...

evaluating Johnson & Johnson (NYSE:JNJ) in comparison to its major competitors within the Pharmaceuticals industry. By analyzing crucial financial metrics, market position, and growth potential ...

After examining Johnson & Johnson, the following trends can be inferred: A Price to Earnings ratio of 24.93 significantly below the industry average by 0.75x suggests undervaluation. This can make the ...

Baltimore settled with opioid manufacturer Johnson & Johnson on the eve of its trial against that company and two ...

The Health Resources and Services Administration threatened Johnson & Johnson with fines and exclusion from the 340B Drug ...

If you’re on the fence about investing in Teva Pharmaceutical Industries Ltd (ADR) or Johnson & Johnson because you’re not sure how they measure up, it’s important to compare them on a few factors ...

As of September 19, 2024, Johnson & Johnson had a $400.0 billion market capitalization, putting it in the 100th percentile of companies in the Pharmaceuticals industry. Currently, Johnson & Johnson’s ...

Approvals are coming fast and furious for Johnson & Johnson’s Rybrevant as it is lining up to challenge the dominance of ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Short Sellers. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands ...

Johnson & Johnson is a holding company ... It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on ...